🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Congratulations to Michael Ke Wang MD FRCPC & David Conen on leading this important meta-analysis. Our results suggest similar rates of bleeding between apixaban, dabigatran & ASA, but higher risk with rivaroxaban vs. ASA. Indirect comparisons across DOACs should be interpreted cautiously.

Individuals with a new cancer diagnosis and no stroke history have an increased risk of ischemic stroke which varies according to site and stage. Future research is needed to identify individuals at highest risk who may benefit from preventative treatment Deborah Siegal

The RENOVE trial found that while low-dose DOACs did not meet non-inferiority for preventing recurrent VTE, it showed a better risk-benefit ratio, with less clinically relevant bleeding. Dose reduction may be a good option for many patients! thelancet.com/journals/lance… Francis Couturaud

In this meta-Analysis of 16 studies (2300+ patients), ✅ Peak & trough concentrations of apixaban and rivaroxaban established 📉 ✅ Age & kidney function impact drug levels—highlighting the need for personalized dosing ✅ Findings align with known pharmacokinetic studies

The Repeat Study addressed a really important knowledge gap! The incidence of recurrent events following an ante- or postpartum VTE is 2.4% person-years. The cumulative risks are 6%, 13%, 17%, and 30% at 2, 5, 10, and 30 years respectively. jthjournal.org/article/S1538-…

🚨How to deal with interference on heparin anti-Xa activity caused by oral factor FXa inhibitors: Communication from the ISTH SSC Subcommittee on Control of Anticoagulation JTH 🙏 Great team work with Adam Cuker MD, MS Lana Castellucci jecko jthjournal.org/article/S1538-…

The CAT-BLED study of 779 cancer patients shows that high GDF-15 levels are linked to major bleeding risks during systemic therapies. It highlights its potential as a key biomarker for bleeding risk prediction & prevention jacc.org/doi/abs/10.101… #JACCCardioOnc #VTE Cihan Ay

Fantastic summary and recommendations on an underappreciated challenge by the ISTH SSC Control of Anticoagulation JTH - FXaI interference with heparin anti-Xa measurement 🧪🩸 Adam Cuker MD, MS Nicolas Gendron Lana Castellucci jthjournal.org/article/S1538-…

Hereditary #antithrombin deficiency and venous thrombosis in pregnancy - results of a retrospective multicenter study jthjournal.org/article/S1538-…

Standardized PAUSE vs complex ASRA periprocedural #DOAC interruption for high #bleed risk procedures: results from PAUSE-2 pilot trial pubmed.ncbi.nlm.nih.gov/40086754/ Vasculearn Network Anticoagulation Forum The PERT Consortium® Thrombosis Canada CanVECTOR Network Thrombosis UK European Thrombosis & Haemostasis Alliance (ETHA) World Thrombosis Day European Society of Cardiology

Post-hoc analysis of the Hokusai VTE Cancer trial showed that treatment for recurrent VTE on AC were heterogeneous, and there were high risks of second recurrent VTE (9%) and major bleeding (10%) within 3 months! doi.org/10.1016/j.jtha… JTH Gary Raskob Marc Carrier

📣🚨I am incredibly happy and proud to share the Prognosis After Transient Ischemic Attack or Minor Stroke (PERSIST) study from my #BantingCanada🇨🇦 postdoctoral fellowship published today in JAMA! jamanetwork.com/journals/jama/…

Prof. Mahé Isabelle presents API-CAT at #ACC2025, published in NEJM Extended anticoagulation with reduced-dose apixaban is noninferior to full-dose for preventing recurrent VTE, with less clinically relevant bleeding 🩸in patients with cancer. nejm.org/doi/full/10.10…

Kudos Keyvan Karkouti et al for this important study

Interesting comments from Geoff Barnes about the #APICAT study #VTE #cancer @ACC25 Assistance Publique – Hôpitaux de Paris (AP-HP) INNOVTE

Emergent cardiac surgery after andexanet-reversal can lead to life-threatening heparin resistance and potential thrombotic complications. ⚠️ Maybe we should avoid FXaI reversal with andexanet in patients who might need urgent cardiac surgery! 👉 Read more doi.org/10.1016/j.jtha…

🚨 Distal Deep Vein Thrombosis in pts admitted to Internal Medicine wards: the AURELIO study ⬇️ 📌 1,458 pts included; asymptomatic distal DVT found in 4% 📌 53% of distal #DVT extended to proximal tract 📌 Active #cancer and pneumonia 🔗 with DDVT 👉 thieme-connect.de/products/ejour…

Have you ever wondered about the long-term risk of recurrence in patients with isolated SSPE? New data suggest the risk may not exceed the threshold for extended duration anticoagulation. Case by case decision is needed. 👉sciencedirect.com/science/articl… Thrombosis Canada CanVECTOR Network

How do you manage oral anticoagulants in patients undergoing an invasive dental procedure? Our prospective national study suggests a short DOAC discontinuation before the invasive dental procedure can minimize bleeding! RPTH doi.org/10.1016/j.rpth…

🎉 Celebrating the end of a remarkable year with our uOttawa | Faculté de médecine, Faculty of Medicine Adult Thrombosis Medicine International Fellows! We're incredibly proud of all you've achieved and the impact you've made. Thank you for your dedication and excellence. 🌍🩸 🇨🇦🇺🇾🇨🇭🇫🇷🇧🇪🇸🇦🇮🇹🇺🇦